Abeona Therapeutics Inc. buy tamam
Summary
This prediction ended on 10.10.18 with a price of €242.86. The BUY prediction by tamam for Abeona Therapeutics Inc. performed very badly with a performance of -40.17%. tamam has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Abeona Therapeutics Inc. | 28.378% | 28.378% | 35.424% | -88.993% |
| iShares Core DAX® | 0.000% | -2.064% | 13.111% | 16.685% |
| iShares Nasdaq 100 | 0.626% | -2.884% | 37.744% | 43.441% |
| iShares Nikkei 225® | 1.568% | -5.892% | 19.592% | 4.617% |
| iShares S&P 500 | 0.334% | -2.281% | 27.745% | 41.046% |
Comments by tamam for this prediction
In the thread Abeona Therapeutics Inc. diskutieren
Abeona Therapeutics is a Buy...
Significant opportunities in various populations were being addressed by lead clinical candidates (Sanfilippo syndrome Type A, Sanfilippo syndrome Type B, Recessive dystrophic epidermolysis bullosa). Receipt of the rare pediatric disease designation for both ABO-102 and ABO-101 meant the company could be eligible for multiple priority review vouchers should the treatments be approved. Certain product candidates had already shown promising preclinical data and early signs of efficacy. One key catalyst coming up is a set of data updates from both ABO-101 and ABO-102 at the WORLD Symposium. After regulatory feedback, the pivotal phase 3 study for EB-101 should get underway in the first half of the year. Further clinical updates throughout the year for ABO-101 and 102 should continue to drive additional upside assuming continued encouraging results. By the end of the year, the juvenile Batten disease and infantile Batten disease programs should enter the clinic as well.